Page 4 - Patrickj Haley News Today

Exelixis (NASDAQ:EXEL – Get Free Report)‘s stock had its “outperform” rating restated by William Blair in a report released on Monday, RTT News reports. Several other equities research analysts have also recently commented on the company. Royal Bank of Canada reissued an “outperform” rating and issued a $26.00 price target on shares of Exelixis in […]

Exelixis, Inc. (NASDAQ:EXEL – Get Free Report)’s stock price reached a new 52-week high during trading on Tuesday . The company traded as high as $23.84 and last traded at $23.72, with a volume of 124977 shares. The stock had previously closed at $23.34. Analysts Set New Price Targets A number of equities research analysts […]

Royal Bank of Canada restated their outperform rating on shares of Exelixis (NASDAQ:EXEL – Free Report) in a research note released on Wednesday morning, Benzinga reports. The firm currently has a $26.00 price objective on the biotechnology company’s stock. A number of other brokerages have also recently commented on EXEL. Stifel Nicolaus restated a hold […]

Equities research analysts at Citigroup assumed coverage on shares of Exelixis (NASDAQ:EXEL – Get Free Report) in a note issued to investors on Friday, Briefing.com reports. The brokerage set a “buy” rating and a $31.00 price target on the biotechnology company’s stock. Citigroup’s price target suggests a potential upside of 32.99% from the company’s previous […]

LSV Asset Management lowered its stake in shares of Exelixis, Inc. (NASDAQ:EXEL – Free Report) by 39.8% in the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 1,267,475 shares of the biotechnology company’s stock after selling 838,909 shares during the quarter. LSV Asset Management owned […]

Exelixis (NASDAQ:EXEL – Get Free Report) was downgraded by research analysts at StockNews.com from a “strong-buy” rating to a “buy” rating in a research report issued on Thursday. A number of other research analysts also recently weighed in on EXEL. SVB Securities began coverage on shares of Exelixis in a research report on Tuesday, August […]

Exelixis (NASDAQ:EXEL – Free Report) had its price target raised by JMP Securities from $24.00 to $27.00 in a research note issued to investors on Tuesday, MarketBeat Ratings reports. The brokerage currently has an outperform rating on the biotechnology company’s stock. EXEL has been the subject of a number of other research reports. StockNews.com initiated […]

Tekla Capital Management LLC purchased a new position in shares of Exelixis, Inc. (NASDAQ:EXEL – Free Report) in the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm purchased 726,639 shares of the biotechnology company’s stock, valued at approximately $14,104,000. Tekla Capital Management LLC owned 0.22% of Exelixis […]

SVB Leerink assumed coverage on shares of Exelixis (NASDAQ:EXEL – Free Report) in a report published on Tuesday, Benzinga reports. The brokerage issued a market perform rating and a $18.00 target price on the biotechnology company’s stock. Several other equities research analysts also recently weighed in on the company. Oppenheimer reaffirmed an outperform rating and […]

Meritage Portfolio Management lifted its stake in Exelixis, Inc. (NASDAQ:EXEL – Get Rating) by 164.8% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 424,235 shares of the biotechnology company’s stock after purchasing an additional 264,052 shares during the quarter. Meritage Portfolio Management’s […]